Publications

5674 Results

Phase II evaluation of Aclarubicin in refractory adult leukemia:A Southwest Oncolog y Group study.

Authors
L Dabich;FE Bull;G Beltran;JW Athens;C Coltman, Jr;JK Weick;EJ Van Slyck;M Amare
Journal / Conference
Cancer Treat Rep 70(8):967-969
Year
1986
Research Committee(s)
Leukemia
Study Number(s)
SWOG-8262

Salvage treatment of poor-prognosis non-Hodgkin's lymphoma withcis-platinum, m-AMSA a nd MGBG: A Southwest Oncology Group study.

Authors
B W Dana;SE Jones;C Coltman, Jr;WJ Stuckey
Journal / Conference
Cancer Treat Rep 70(2):291-292
Year
1986
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8264

A phase-II study of fludarabine phosphate for the treatment ofadvanced non-small cell carcinoma of the lung - A Southwest OncologyGroup study.

Authors
GR Weiss;JJ Crowley;DD Von Hoff;SA Taylor;RJ Belt;C Coltman, Jr;HE Hynes;JJ Costanzi
Journal / Conference
Cancer Treat Rep 70(9):1123-1124
Year
1986
Research Committee(s)
Lung
Study Number(s)
SWOG-8464

Adjuvant therapy of breast cancer: Southwest Oncology Group studies.

Authors
CK Osborne;SE Rivkin;RW McDivitt;S Green;RL Stephens;JJ Costanzi;R O'Bryan
Journal / Conference
NCI Monographs 1:71-74
Year
1986

CHOP is curative in thirty percent of patients with diffuse largecell lymphoma: A twelve year Southwest Oncology Group followup.

Authors
C Coltman, Jr;S Dahlberg;SE Jones;TP Miller;BW Dana;EM McKelvey;RJ Hartsock;DO Dixon
Journal / Conference
ASCO 5:197(#774)
Year
1986
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-7204/7205, SWOG-7426/7427, SWOG-7713/14

Adjuvant chemotherapy for operable breast cancer with positiveaxillary nodes.

Authors
H Glucksberg;SE Rivkin;S Green;B Metch;CK Osborne;R McDivitt;R Stevens;J Costanzi
Journal / Conference
ASCO 5:68(#265)
Year
1986
Research Committee(s)
Breast
Study Number(s)
SWOG-7436

The prognosis of exophytic large bowel tumors. Data from aSouthwest Oncology Group adjuvant study and the University of ArkansasMedical Science Campus.

Authors
F Panettiere;AR Rogers
Journal / Conference
ASCO :#C-306
Year
1986
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-7510

Adjuvant chemotherapy for poor prognosis estrogen receptornegative stage II, III breast cancer one year versus two years CMFVP.

Authors
S Rivkin;S Green;B Metch;CK Osborne;WA Knight;R McDivitt;A Cruz;D Tesh;J Costanzi;S Balcerzak;R Stevens
Journal / Conference
ASCO :#C-266
Year
1986
Research Committee(s)
Breast
Study Number(s)
SWOG-7827

Age and patient outcome in limited small cell lung cancer. TheSouthwest Oncology Group(SWOG) experience.

Authors
BA Neilan;R Paloyan;J Crowley;JG Mira;MS Kies
Journal / Conference
ASCO 5:182(#713)
Year
1986
Research Committee(s)
Lung
Study Number(s)
SWOG-7924

Randomized Phase III trial of doxorubin (D) + cyclophosphamide (C)+ BCG vs. DC + cisplatin (P) vs. DC +P + BCG in stages III & IVovarian cancer (OV CA).

Authors
D Alberts;N Mason;R O'Toole;R Kronmal;R Hilgers;E Surwit;H Eyre;L Baker;J Boutselis;S Rivkin;B Green;E Hannigan
Journal / Conference
ASCO 5:119(#462)
Year
1986
Research Committee(s)
Gynecologic
Study Number(s)
SWOG-7925